Walgreens Boots Alliance, Inc. Sells 1,859,390 Shares of Cencora, Inc. (NYSE:COR) Stock (2024)

Cencora, Inc. (NYSE:COR - Get Free Report) major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the sale, the insider now directly owns 24,418,171 shares of the company's stock, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Cencora Stock Down 0.4 %

• Teva Pharma is the way to play the re-rise of generic drugs

Shares of NYSE:COR traded down $0.93 during mid-day trading on Friday, reaching $218.89. 1,029,855 shares of the stock were exchanged, compared to its average volume of 1,467,893. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. The company has a market cap of $43.66 billion, a P/E ratio of 23.95, a P/E/G ratio of 1.53 and a beta of 0.47. Cencora, Inc. has a one year low of $163.37 and a one year high of $246.75. The stock's 50 day simple moving average is $233.86 and its 200-day simple moving average is $222.31.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping the consensus estimate of $3.65 by $0.15. The company had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.50 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Announces Dividend

• Eli Lilly, McKesson, Novartis Flash Promising Chart Action

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a $0.51 dividend. The ex-dividend date was Thursday, May 9th. This represents a $2.04 annualized dividend and a yield of 0.93%. Cencora's dividend payout ratio is presently 22.32%.

Hedge Funds Weigh In On Cencora

A number of institutional investors have recently modified their holdings of COR. Rise Advisors LLC bought a new stake in Cencora during the 1st quarter worth $25,000. Legacy Bridge LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $27,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $29,000. TFO Wealth Partners LLC acquired a new position in Cencora during the 1st quarter worth approximately $30,000. Finally, LRI Investments LLC acquired a new position in Cencora during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

• 3 High Dividend REITs That Analysts Are Bullish On

Several research firms have recently commented on COR. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 2nd. Mizuho lifted their target price on Cencora from $192.00 to $224.00 and gave the stock a "neutral" rating in a report on Monday, February 5th. SVB Leerink started coverage on Cencora in a research report on Monday, February 26th. They set an "outperform" rating and a $261.00 price objective for the company. Robert W. Baird raised their price objective on Cencora from $275.00 to $277.00 and gave the company an "outperform" rating in a research note on Thursday, May 2nd. Finally, Leerink Partnrs restated an "outperform" rating on shares of Cencora in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $233.90.

Get Our Latest Stock Analysis on COR

Cencora Company Profile

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Read More

• Five stocks we like better than Cencora
• Energy and Oil Stocks Explained
• MarketBeat Week in Review – 5/20 - 5/24
• Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
• NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
• Technology Stocks Explained: Here's What to Know About Tech
• These 2 Retail Traders Favorites are Nearing Major Breakouts

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected].